Summary

Jaimin focuses his practice on patent litigation and counseling related to pharmaceuticals and biosimilars. He has also branched out of the pharmaceutical area, taking his patent litigation expertise into other technology areas such as software and mechanical systems.

Jaimin has represented world-class pharmaceutical companies in various phases of patent litigation, including generic versions of: Gilenya (fingolimod), Xeljanz (tofacitinib), Abilify (aripiprazole), Pazeo (olopatadine 0.7%), and the isosulfan blue dye.  He has extensive experience working with experts to develop scientific non-infringement and/or invalidity defenses, and drafting related reports.  Jaimin has also assisted in all aspects of a preliminary injunction proceeding, including deposing a technical expert and drafting the appellate briefs.

In addition to pharmaceutical and life sciences patent litigation, Jaimin counsels pharmaceutical companies on FDA-related matters, such as Orphan Drug Exclusivity and Competitive Generic Therapy (CGT) Exclusivity.  Recently, he played an instrumental role in the first ever dispute involving CGT exclusivity.  There, he tackled challenging statutory interpretation issues and formulated incisive analyses to advance the client’s positions. 

Jaimin also analyzes license and settlement agreements of pharmaceutical companies to advise on the appropriate course of action, including the timing of commercial launch of drugs. Finally, he counsels clients in connection with proposed legislation, such the BLOCKING ACT of 2019 and the FAIR Generics Act.  His counsel includes proposing amendments to drafts of bills for Congress to consider.

Outside of pharma, Jaimin is representing the patentee-plaintiffs in a hotly contested case involving fire-resistive glass flooring in the Northern District of California.  He is also the “go-to” associate, again on the patentee-plaintiffs’ side, in a litigation involving children’s swings in the District Court of Colorado.  In addition, he has represented clients in litigation involving software patents in the Eastern District of Texas and the Northern District of Ohio. 

Prior to attending law school, Jaimin worked at a large India-based generic pharmaceuticals company. As a manager in the company’s Intellectual Property Cell, he gained first-hand knowledge in litigation strategy and the business realities that inform company decisions. Before joining Taft, Jaimin was an associate in the Chicago office of another national law firm, where he focused primarily on Hatch-Waxman matters. 

Jaimin received a B.Sc.in biochemistry from St. Xavier’s College and an M.Sc. in biotechnology from the Indian Institute of Technology-Bombay. His J.D. is from The John Marshall Law School, cum laude, where he received the CALI award in Professional Responsibility and International Law. Jaimin was a judicial extern for the Hon. James F. Holderman and the Hon. Virginia M. Kendall in the U.S. District Court for the Northern District of Illinois.

Pro Bono
As part of his pro bono efforts, Jaimin obtained a favorable settlement for a middle school student in an expulsion matter after conducting an evidentiary hearing in front of the Board of Education for the school district.  Jaimin also obtained a favorable settlement for a plaintiff as part of mediation in a section 1983 case.  He is currently representing an artist against a county in a contract dispute involving children’s sculpture.

Education

  • The John Marshall Law School (2016)
  • Indian Institute of Technology, Bombay (2004)
  • St. Xavier's College, Ahmedabad (2001)

Admissions

  • State - Illinois
  • Federal - Northern District of Illinois
  • Federal - District of Colorado

Speeches and Publications

Speaking Engagements

  • "Competitive Generic Therapy Exclusivity," 8th Annual Pharma IPR Conference, Mumbai, India (March 6, 2019)

Publications

  • "For Now, Competitive Generic Therapy Exclusivity is a Mirage," (co-author with Stephen Auten and Sinchan Shah), Law360 (Feb. 26, 2019)
  • Evidence in Patent Cases, ch.12 (Kenneth L. Dorsney et al. eds., 1st ed. 2018) (co-author)
  • "Must Whole Patent Be Nixed To Forfeit 180-Day Exclusivity?," (co-author with Steve Auten) Law360 (July 25, 2018)
  • "Pulling the ‘Trigger’ on the Hatch-Waxman Act's 180-Day Exclusivity Using Inter Partes Review," The John Marshall Review of Intellectual Property Law (May 2015)
  • "Effects of pH and Ionic Strength on the Assembly and Bundling of FtsZ Protofilaments: A Possible Role of Electrostatic Interactions in the Bundling of Protofilaments," (co-author) International Journal of Biological Macromolecules (2006)

Professional Affiliations

  • Intellectual Property Law Association of Chicago

    Member

  • Chicago Bar Association

    Member